Skip To Main Content
Lilly
Menu closed
Lilly
  • Medical Home
  • Medical Education
      • All Therapeutic Areas
        • Alopecia Areata
        • Atopic Dermatitis
        • Psoriasis
        • Diabetes
        • Hypoglycemia
      • Gastroenterology
      • Infectious Disease
      • Neuroscience
      • Oncology
      • Rheumatology
      • Tools for Communication
      • All Therapeutic Areas
      • Dermatology
        • Diabetes
        • Hypoglycemia
      • Neuroscience
      • Oncology
      • Osteoporosis
      • Rheumatology
      • Well-Being
  • Chat Contact Us

2022 ADA Guideline Expansion on CGM Recommendations and The Impact to Patients with T2D

At the completion of this session the audience will be able to recognize the importance of a CGM, how it is beneficial in the T2D population, and its impact on the hypoglycemia prevention and preparedness.

Date of Last Review: August 05, 2022

Document Number: VV-MED-121523

Are you satisfied with this content?
  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

To speak to customer support:
Call (XXX) XXX-XXXX

This site is intended for US Healthcare Professionals only.

4.0.3 08/2022 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2022. All rights reserved.

Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

Facebook Twitter
Lilly